Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Pramlintide

Stage Phase 2/3Stale

Sponsor AstraZeneca

Route oral and injection

Class Amylin

Mechanism amylin analog

Sources

registry, as of 2026-04-17Stale

https://clinicaltrials.gov/study/NCT06619015

Tailoring Obesity Treatment Trial. Overall status WITHDRAWN. Phases PHASE2,PHASE3. Lead sponsor Esbjerg Hospital - University Hospital of Southern Denmark. Enrollment 0. Conditions Obesity; Appetite Regulation; PreDiabetes. The two main aims of this clinical study is; 1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication 2. To investigate the effect of combining semaglutide and

ClinicalTrials.gov NCT06619015 protocol and results modules

registry, as of 2015-04-15Stale

https://clinicaltrials.gov/study/NCT00673387

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 636. Conditions Overweight; Obesity. A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects. nausea Placebo 4 diarrhea Placebo 5 vomiting Placebo 0 nausea Pramlintide 360 mcg 31 diarrhea Pramlintide 360 mcg 5 vomiting Pramlintide 360 mcg 6 nausea Metreleptin 5.0 mg 4 diarrhea Metreleptin 5.0 mg 3 vomiting Metreleptin 5.0 mg 3 nausea Pramlintide 180 mcg + Metreleptin 2.5 mg 27 diarrhea Pramlintide 180 mcg + Metreleptin 2.5 mg 5 vomiting Pram

ClinicalTrials.gov NCT00673387 protocol and results modules

registry, as of 2015-04-10Stale

https://clinicaltrials.gov/study/NCT00112021

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 400. Conditions Obesity. This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

ClinicalTrials.gov NCT00112021 protocol and results modules

registry, as of 2015-04-15Stale

https://clinicaltrials.gov/study/NCT00819234

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 274. Conditions Obesity. Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide a nausea 360 mcg Pramlintide + 1.25mg Metreleptin - Stable 3 diarrhea 360 mcg Pramlintide + 1.25mg Metreleptin - Stable 1 vomiting 360 mcg Pramlintide + 1.25mg Metreleptin - Stable 0 nausea 360 mcg Pramlintide + 2.5 Metreleptin - Stable 2 diarrhea 360 mcg Pramlintide + 2.5 Metreleptin - Stable 2 vomiting 360 mcg Pramlintide + 2.5 Metreleptin - Sta

ClinicalTrials.gov NCT00819234 protocol and results modules

registry, as of 2015-03-06Stale

https://clinicaltrials.gov/study/NCT00402077

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 258. Conditions Overweight; Obesity. This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.

ClinicalTrials.gov NCT00402077 protocol and results modules

registry, as of 2015-04-15Stale

https://clinicaltrials.gov/study/NCT01235741

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects. Overall status TERMINATED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 213. Conditions Obesity. Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1 of 2 treatment arms (pramlintide+metreleptin or plac Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population Week 1 Placebo -0.34 percentage of change in weight Baseline up to Month 6 Follow-Up Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population Week 1 Pramlintide + Metreleptin -0.26 percentage of change in weight Baseline up to Month 6 Foll

ClinicalTrials.gov NCT01235741 protocol and results modules

registry, as of 2015-06-11Stale

https://clinicaltrials.gov/study/NCT00189514

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 210. Conditions Obesity. This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

ClinicalTrials.gov NCT00189514 protocol and results modules

registry, as of 2015-06-11Stale

https://clinicaltrials.gov/study/NCT00444561

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 184. Conditions Overweight; Obesity. This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tole

ClinicalTrials.gov NCT00444561 protocol and results modules

registry, as of 2015-04-14Stale

https://clinicaltrials.gov/study/NCT00392925

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 177. Conditions Overweight; Obesity. This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously. nausea Placebo + Metreleptin 7 diarrhoea Placebo + Metreleptin 0 vomiting Placebo + Metreleptin 2 nausea Pramlintide + Placebo 8 diarrhoea Pramlintide + Placebo 3 vomiting Pramlintide + Placebo 1 nausea Participants Not Randomized to Group After Lead-In Period 10 diarrhoea Participants Not Randomized to Group After Lead-In Period 2 vomiting Participants Not Randomized to Group After Lead-In Period 3

ClinicalTrials.gov NCT00392925 protocol and results modules

registry, as of 2015-10-21Stale

https://clinicaltrials.gov/study/NCT00042601

Evaluation of the Effect of Pramlintide on Satiety and Food Intake. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 51. Conditions Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2. This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.

ClinicalTrials.gov NCT00042601 protocol and results modules

registry, as of 2018-11-16Stale

https://clinicaltrials.gov/study/NCT00690235

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia. Overall status COMPLETED. Phases PHASE4. Lead sponsor University of Texas Southwestern Medical Center. Enrollment 33. Conditions Schizophrenia; Schizoaffective Disorder; Diabetes; Weight Gain. Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.

ClinicalTrials.gov NCT00690235 protocol and results modules

registry, as of 2026-04-01Stale

https://clinicaltrials.gov/study/NCT07506369

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans. Overall status RECRUITING. Phases NA. Lead sponsor University Hospital, Gentofte, Copenhagen. Enrollment 18. Conditions Obesity & Overweight. The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabol

ClinicalTrials.gov NCT07506369 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06619015

semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide. The results from this study will contribute to identifying possible predictors of treatment r

NCT06619015 description or intervention text

Studies

TOTT

Registry NCT06619015

Phase Phase 2/3

Status Withdrawn

Enrollment 0

Start 2025-04-01

Primary completion 2025-04-01

Study completion 2025-04-01

Catalyst Primary completion. 2025-04-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide and placebo

Regimen weekly

Weeks 26

Population Obesity; Appetite Regulation; PreDiabetes

Semaglutide and pramlintide

Regimen weekly

Weeks 26

Comparator placebo

Population Obesity; Appetite Regulation; PreDiabetes

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Registry NCT00673387

Phase Phase 2

Status Completed

Enrollment 636

Placebo-P + Placebo-M

Population Overweight; Obesity

participants with nausea, 4 participantsStale

participants with diarrhea, 5 participantsStale

participants with vomiting, 0 participantsStale

Pramlintide 360 mcg + Placebo-M

Dose 360 mcg

Population Overweight; Obesity

participants with nausea, 31 participantsStale

participants with diarrhea, 5 participantsStale

participants with vomiting, 6 participantsStale

Placebo-P + Metreleptin 5.0 mg

Dose 5.0 mg

Population Overweight; Obesity

participants with nausea, 4 participantsStale

participants with diarrhea, 3 participantsStale

participants with vomiting, 3 participantsStale

Pramlintide 180 mcg + Metreleptin 2.5 mg

Dose 2.5 mg

Comparator placebo

Population Overweight; Obesity

participants with nausea, 27 participantsStale

participants with diarrhea, 5 participantsStale

participants with vomiting, 0 participantsStale

Pramlintide 180 mcg + Metreleptin 5.0 mg

Dose 5.0 mg

Comparator placebo

Population Overweight; Obesity

participants with nausea, 21 participantsStale

participants with diarrhea, 4 participantsStale

participants with vomiting, 2 participantsStale

Pramlintide 360 mcg + Metreleptin 1.25 mg

Dose 1.25 mg

Comparator placebo

Population Overweight; Obesity

participants with nausea, 26 participantsStale

participants with diarrhea, 4 participantsStale

participants with vomiting, 5 participantsStale

Pramlintide 360 mcg + Metreleptin 2.5 mg

Dose 2.5 mg

Comparator placebo

Population Overweight; Obesity

participants with nausea, 29 participantsStale

participants with diarrhea, 7 participantsStale

participants with vomiting, 1 participantsStale

Pramlintide 360 mcg + Metreleptin 5.0 mg

Dose 5.0 mg

Comparator placebo

Population Overweight; Obesity

participants with nausea, 19 participantsStale

participants with diarrhea, 3 participantsStale

participants with vomiting, 1 participantsStale

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Registry NCT00112021

Phase Phase 2

Status Completed

Enrollment 400

Pramlintide Acetate

Comparator placebo

Population Obesity

Placebo

Population Obesity

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Registry NCT00819234

Phase Phase 2

Status Completed

Enrollment 274

1

Regimen twice daily

Population Obesity

participants with nausea, 3 participantsStale

participants with diarrhea, 1 participantsStale

participants with vomiting, 0 participantsStale

2

Regimen twice daily

Comparator placebo

Population Obesity

participants with nausea, 2 participantsStale

participants with diarrhea, 2 participantsStale

participants with vomiting, 0 participantsStale

3

Regimen twice daily

Comparator placebo

Population Obesity

participants with nausea, 5 participantsStale

participants with diarrhea, 1 participantsStale

participants with vomiting, 0 participantsStale

4

Regimen twice daily

Comparator placebo

Population Obesity

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Registry NCT00402077

Phase Phase 2

Status Completed

Enrollment 258

1

Regimen once daily

Comparator placebo

Population Overweight; Obesity

2

Regimen once daily

Comparator placebo

Population Overweight; Obesity

3

Regimen once daily

Comparator placebo

Population Overweight; Obesity

4

Regimen once daily

Population Overweight; Obesity

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Registry NCT01235741

Phase Phase 2

Status Terminated

Enrollment 213

Group A

Regimen once daily

Weeks 16

Comparator placebo

Population Obesity

Group B

Regimen once daily

Weeks 16

Population Obesity

Placebo

Regimen once daily

Population Obesity

percent change in body weight, -0.34 %Stale

participants with nausea, 1 participantsStale

Pramlintide + Metreleptin

Regimen once daily

Population Obesity

percent change in body weight, -0.26 %Stale

participants with nausea, 7 participantsStale

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Registry NCT00189514

Phase Phase 2

Status Completed

Enrollment 210

1

Comparator placebo

Population Obesity

2

Comparator placebo

Population Obesity

3

Comparator placebo

Population Obesity

4

Population Obesity

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Registry NCT00444561

Phase Phase 2

Status Completed

Enrollment 184

Pramlintide acetate (AC137)

Population Overweight; Obesity

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Registry NCT00392925

Phase Phase 2

Status Completed

Enrollment 177

Placebo and Metreleptin

Population Overweight; Obesity

Pramlintide Acetate and Placebo

Population Overweight; Obesity

participants with nausea, 7 participantsStale

participants with diarrhoea, 0 participantsStale

participants with vomiting, 2 participantsStale

Pramlintide Acetate and Metreleptin

Comparator placebo

Population Overweight; Obesity

Lead-In Period

Comparator placebo

Population Overweight; Obesity

participants with nausea, 10 participantsStale

participants with diarrhoea, 2 participantsStale

participants with vomiting, 3 participantsStale

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

Registry NCT00042601

Phase Phase 2

Status Completed

Enrollment 51

Placebo

Population Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Pramlintide

Comparator placebo

Population Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Registry NCT00690235

Phase Phase 4

Status Completed

Enrollment 33

Placebo

Regimen twice daily

Population Schizophrenia; Schizoaffective Disorder; Diabetes; Weight Gain

Pramlintide

Regimen twice daily

Comparator placebo

Population Schizophrenia; Schizoaffective Disorder; Diabetes; Weight Gain

APP

Registry NCT07506369

Phase Not applicable

Status Recruiting

Enrollment 18

Amylin (Pramlintide) + Placebo

Population Obesity & Overweight

PP + Placebo

Population Obesity & Overweight

Amylin (Pramlintide) + PP

Comparator placebo

Population Obesity & Overweight

Placebo + Placebo

Population Obesity & Overweight